CGEM Q3 2021 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$841M

Q3 2021 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$18M

Net Income

-$17M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$453M

Total Liabilities

$8M

Stockholders' Equity

$443M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$18M	-$11M	-59.8%
Net Income	-$17M	-$10M	-76.0%